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Prohibitins (PHBs) are scaffold proteins that modulate many signaling pathways controlling cell survival,
metabolism, and inflammation. Several drugs that target PHBs have been identified and evaluated for various
clinical applications. Preclinical and clinical studies indicate that these PHB ligands may be useful in
oncology, cardiology, and neurology, as well as against obesity. This review covers the physiological role
of PHBs in health and diseases and current developments concerning PHB ligands.Introduction
Prohibitin-1 (PHB1, formerly known as BAP32) and its homolog
PHB2 (formerly BAP37, REA, or prohibitone) are pleiotropic
proteins with multiple functions. PHB1 was initially identified in
1989 by McClung and collaborators by screening for potential
tumor suppressors with antiproliferative activities that were
highly expressed in normal resting, but not regenerating, rat liver
(McClung et al., 1989; Nuell et al., 1991). PHBs have since been
shown to act as a hub for many signaling pathways triggered by
growth factors, the immune response, and steroid hormones
regulating metabolism, mitochondrial biogenesis, cell migration,
division, and survival.
PHBs are composed of an N-terminal transmembrane
domain, an evolutionarily conserved PHB domain that is com-
mon to other scaffold proteins (including stomatin, flotillin, and
HflK/C), and a C-terminal coiled-coil domain that is involved in
the interaction between PHB1 and PHB2 (Figure S1 available
online). Although the structure of PHBs has not been solved,
Winter et al. (2007) were able to generate structural models of
human PHBs based on the known structure of flotillin-2, which
belongs to the same family of membrane proteins.
Mitochondrial Functions of PHBs
Located in the mitochondrial inner membrane, PHB1 and PHB2
interact with each other to form heterodimers that are organized
in ring-like structures with a diameter of 20–25 nm (Figure 1;
Back et al., 2002; Coates et al., 2001). These supercomplexes
maintain the structure of mitochondria and regulate their func-
tions (Tatsuta et al., 2005). PHBs protect newly imported pro-
teins from degradation by the m-AAA (mitochondrial ATPases
Associated with diverse cellular Activities) protease (Steglich
et al., 1999), promote mitochondrial protein synthesis (He
et al., 2012), maintain the organization and copy number of mito-
chondrial DNA (mtDNA; Kasashima et al., 2008), and act as
a chaperones for newly synthesized proteins of the mitochon-
drial complex I (Nijtmans et al., 2000, 2002) and theGTPase optic
atrophy 1 (Opa1) during mitochondrial fission and morphogen-
esis (Merkwirth et al., 2008). PHB1 also interacts with the adaptor
protein p66Shc, a major mediator of stress-induced apoptosis316 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All r(Madireddi, 2006). This adaptor protein is activated by UVC,
H2O2, and reactive oxygen species (ROS), and induces the
generation of ROS in mitochondria, leading to apoptosis (Gertz
et al., 2008). It remains unclear whether PHB1 modulates this
proapoptotic response; nevertheless, it is tempting to speculate
that p66Shc is involved in the cytoprotective activities of PHBs
and their ligands, particularly against oxidative stress (Bernard
et al., 2011; Fahrig et al., 2005; Kathiria et al., 2012a; Liu, et al.,
2009b; Ribeiro et al., 2012a).
PHB2 is also regulated by a second messenger, sphingosine-
1-phosphate (S1P), which controls diverse physiological pro-
cesses through several targets. S1P binds with high affinity to
PHB2 and thereby maintains the integrity of the mitochondrial
respiration machinery (Strub et al., 2011). This process is
involved in the preconditioning protection of the heart against
ischemia-reperfusion injury (Gomez et al., 2011).
Regulation and Physiological Role of PHBs
PHBs are not limited to mitochondria; they are also found in the
nucleus, the endoplasmic reticulum, the plasma membrane, and
macrophage phagosomes (Garin et al., 2001), where theymodu-
late many aspects of cell physiology. Their roles are extremely
complex, partly because PHBs are themselves regulated by
several tyrosine and serine phosphorylations, O-GlcNAc modifi-
cations, palmitoylations, transamidations, and tyrosine nitrosyla-
tions (Mishra et al., 2010). PHB1 interacts physically with the
second messenger PIP3, and PHB2 interacts with S1P (Ande
and Mishra, 2009; Strub et al., 2011).
Each posttranslational modification of the PHBs has sub-
stantial effects on their activity (Figure 2). One of the best-
documented examples is Akt phosphorylation of PHB1 at
Thr258, which blocks its interaction with Shp1/2 and facilitates
Akt signaling (Ande and Mishra, 2009). Shp1/2 is a phosphatase
that facilitates Akt signaling and enhances insulin signaling.
Additionally, the phosphorylation of PHB1 at Thr258 is necessary
for the activation of C-Raf (Raf-1) by Ras (Chiu et al., 2013).
Rajalingam et al. (2005) established that the activation of
C-Raf by Ras requires the heterodimerization of phospho-
PHB1(Thr258) with C-Raf. The phosphorylation of PHB1 atights reserved
Figure 1. Function of PHB1 and PHB2 in
Mitochondria
In the mitochondrial inner membrane, PHB1 and
PHB2 are organized in ring-like structures that
maintain the structure and regulate the functions
of mitochondria through interaction with OPA-1,
m-AAA protease, SLP-2 (stomatin-like protein 2),
ATAD3 (ATPase family AAA Domain-containing
protein 3), and mtDNA.
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Akt and C-Raf/ERK pathways, which promote proliferation and
metastasis (Chiu et al., 2012). By contrast, insulin-receptor-
induced phosphorylation of PHB1 at Tyr114 promotes its
heterodimerization with the phosphatase Shp1 and blocks Akt
signaling (Ande et al., 2009a).
It has been suggested that the regulation of PHB1 by trans-
forming growth factor b (TGF-b) is responsible for the dual effect
of this cytokine in prostate cancer (Zhu et al., 2010). In the early
stage of tumorigenesis, TGF-b acts as a tumor suppressor,
but subsequently it promotes metastatic spread during cancer
progression. The binding of TGF-b to its receptor triggers the
C-Raf/MEK/ERK pathway and also activates Smad 2/3 or
Smad 1/5, thereby causing opposite effects (Figure 2). ERK acti-
vates protein kinase C d (PKC-d), which leads to the phosphory-
lation of PHB1 and consequently to cell survival and invasion.
However, Smad signaling also upregulates 14-3-3 protein, which
inhibits PKC-d, leading to a hypophosphorylation of PHB1 that
promotes apoptosis.
The activity of PHB2 is regulated by serine and threonine
phosphorylation, in particular at Ser91 and Tyr248 (Ross et al.,
2008; Sun et al., 2011). Calcium/calmodulin-dependent protein
kinase IV (CaMKIV) phosphorylates PHB2 at Ser91, impeding
its ability to repress the transcriptional activity of myocyte
enhancer factor 2 (MEF2; Sun et al., 2011). The consequence
of this phosphorylation of PHB2 on the activity of other
transcription factors has not been reported. PHB2 also inhibits
circadian transcription by interacting with casein kinase 1 ε
(CK1ε; Kategaya et al., 2012).
PHBs have been detected at the surface of platelets, micro-
glial cells (Wintachai et al., 2012), endothelial cells in adipose
tissue (Kolonin et al., 2004), paclitaxel-resistant cancer cells
(Patel et al., 2010), intestinal epithelial cells (Sharma and Qadri,
2004), and activated T cells (Yurugi et al., 2012). In platelets,
PHB1 and PHB2 interact directly with protease-activated re-
ceptor 1 (PAR1) to promote platelet aggregation (Zhang et al.,Chemistry & Biology 20, March 21, 20132012). The physiological role of PHB1 at
the surface of microglial cells and endo-
thelial cells of adipose tissue remains
elusive, but it has been demonstrated
that PHB1 at the surface of cancer cells
is involved in resistance to paclitaxel
(Patel et al., 2010). A virulence antigen
of Salmonella typhi, the causative agent
of typhoid, interacts with PHB1 and
PHB2 at the surface of intestinal epi-
thelial cells, resulting in downregulation
of the mitogen-activated protein kinase
(MAPK) cascade and inhibition of earlyinflammatory responses (Patel et al., 2010). Similarly, consider-
able proportions of total PHB1 and PHB2 are located on the
surface of activated T cells, where they contribute to the activa-
tion of ERK induced by T cell activation (Yurugi et al., 2012).
PHB1 is also present in human serum, embedded in lipid
droplets where it interacts with the complement protein C3 to
promote innate immunity (Mishra et al., 2007). Interestingly,
serum PHB1 and PHB2 concentrations were found to be signif-
icantly elevated in patients with colorectal cancer, suggesting
that they may serve as a biomarker for this type of cancer
(Mengwasser et al., 2004).
A brief presentation of the interactions between PHBs and
other proteins is provided in Table 1 (for a list of other putative
partners of PHB1, see Table S1).
PHBs and Cancer
Both PHB1 and PHB2 are involved in growth, resistance to
chemotherapy, and metastasis through several mechanisms,
including activation of the Ras-C-Raf-MEK-ERK pathway,
modulation of TGF-b signaling, and transcriptional regulation.
Indeed, PHB1 interacts with the transcription factor p53 in the
nucleus of cancer cells to increase its transcriptional activity
(Fusaro et al., 2003). p53 is a tumor suppressor that controls
the cell cycle, apoptosis, genomic stability, and angiogenesis
(Chander et al., 2010, 2011; Fusaro et al., 2003; Joshi et al.,
2007). A component of ubiquitin ligase complexes, Skp2B,
which is overexpressed in many breast cancers, interacts with
both PHB1 and PHB2 to promote their degradation (Chander
et al., 2010, 2011; Umanskaya et al., 2007). Because PHB1
acts as an activator (Fusaro et al., 2003) and chaperone
(Chander et al., 2011) for p53, this depletion in PHB1 leads to
an attenuated activity of p53 in cancer cells overexpressing
Skp2B and consequently promotes their survival.
PHB1 is also an important regulator of the retinoblastoma
tumor suppressor protein (Rb) and its family members P107
and p130 (Wang et al., 1999b). These proteins bind and inhibitª2013 Elsevier Ltd All rights reserved 317
Figure 2. PHB Signaling
PHBs integratemany signaling pathways (e.g., Akt,
C-RAF-MEK-ERK, CaMK, and PKC) to orches-
trate various aspects of cell physiology, including
metabolism, transcription, apoptosis/survival,
cytoskeleton reorganization, and differentiation.
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represses the activity of E2F transcription factors by interacting
with several proteins, including Rb, histone deacetylases
(HDACs), and the nucleosome-remodeling proteins Brg-1 and
Brm (Wang et al., 1999a, 1999b, 2002).
A growing body of evidence indicates that the cellular localiza-
tion of PHBs is a determinant of their function, especially in
cancer cells. Patel et al. (2010) found that PHB1 is overex-
pressed on the surface of cancer cells that are resistant to
taxoids, doxorubicin, and etoposide. They also demonstrated
that the redirection of PHB1 from the cytoplasm to the cell
surface is critical for drug resistance, and their work suggests
that cell-surface PHB1 may serve as a biomarker of chemore-
sistance in cancer patients.
In normal epithelial breast cells, PHB1 is located primarily in the
mitochondria, but in invasive and noninvasive breast cancer cells
it is mainly confined to the nucleus, suggesting that PHB1 local-318 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rights reservedization is associated with tumorigenesis
(Chen et al., 2011). Confocal microscopy
experiments demonstrated that PHBs
colocalize with the proto-oncogenes
c-myc, c-fos, p53, and Rb in neuroblas-
toma SK-N-SH cells (Li et al., 2011).
Treatment with the anticancer drug
camptothecin leads to PHB1 and p53
being exported from the nucleus to the
mitochondria of breast cancer cell lines
(Fusaro et al., 2003). This camptothecin-
induced translocation of PHB1, which is
dependent on the protein transporter
CRM-1, occurs preferentially in trans-
formed cell lines and not in untrans-
formed or primary cells. A peptide corre-
sponding to the nuclear export signal of
PHB1 prevented the export of PHB1,
resulting in the protection of cells from
apoptosis, indicating that the transloca-
tion of PHB1 from the nucleus to the
mitochondria contributes to its tumor-
suppressive effects (Rastogi et al.,
2006b). One mechanism by which the
intracellular location of PHBs is con-
trolled involves the signaling protein
BIG3/WDR5, which traps PHB2 in the
cytoplasm and consequently stimulates
the estrogen-signaling pathway in the
hormone-related growth of breast cancer
cells (Kim et al., 2009).
Beyond these activities of PHBs as
proteins, the 30-UTR of PHB1 messenger
RNA (mRNA) was found to suppress both the proliferation of
human breast cancer cells in vitro and the growth of breast
tumors in xenografted mice in vivo (Manjeshwar et al., 2003).
This was the first demonstration that an RNA molecule can func-
tion as a tumor suppressor in human breast cancer.
The tumor-suppressor activity of PHB1 and its mRNA 30-UTR
is further supported by the discovery that the oncogenic micro-
RNA-27a (miR-27a), which is upregulated in many cancers
(Chhabra et al., 2010), targets the 30-UTR of PHB1 and downre-
gulates PHB1 in human gastric adenocarcinoma (Liu et al.,
2009a). Fletcher et al. (2012) demonstrated that miR-27a is upre-
gulated by androgen receptor in prostate cancer, resulting in
reduced PHB1 mRNA and protein levels and increased cancer
cell growth. Interestingly, adding PHB1 to cells overexpressing
miR-27a blocked miR-27a-induced growth, demonstrating that
the oncogenic activity of miR-27a strongly involves PHB1
signaling in prostate cancer.
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display both anti- and protumorigenic roles in cancers (summa-
rized in Table 2). This dichotomy may reflect the heterogeneity
of cancer cell types, which are manifested by an alteration of
different signaling pathways. Consequently, the regulation of
transcription, translation, and posttranslational modification
of PHBs probably depends on the cancerous cell type
involved. These posttranslational events (e.g., phosphorylation,
SUMOylation, O-GlcNAc modification, palmitoylation, and
transamidation) modulate both the subcellular localization of
PHBs and their downstream effects on proliferation and survival
of cells. On the cell surface PHB1 promotes chemoresistance,
but on the inner face of the plasma membrane it can contribute
to the oncogenic activation of C-Raf. However, it is tempting to
speculate that in the nucleus PHB1 displays antitumorigenic
activity due to its action on p53, Rb, p107, p130, and com-
ponents of the mammalian replication machinery. Additional
studies are required to decipher the roles played by signaling
and intracellular localization of PHBs in oncogenesis.
PHBs and Cytoprotection
Many studies have indicated that PHBs protect cells from oxida-
tive stress, which is due to an excessive production or an
impaired elimination of ROS (Jones, 2008). It is closely associ-
ated with mitochondrial dysfunction and is an important compo-
nent of the etiology of cancers, inflammatory, cardiovascular,
and neurodegenerative diseases, and diabetes mellitus. In
view of the central role of PHBs in maintaining the normal struc-
ture and function of mitochondria, it is unsurprising that PHBs
can alleviate the deleterious effect of oxidative stress.
Many stresses, in particular oxidative stress, upregulate PHB1
and PHB2 to promote cell survival. Indeed, PHB1 expression is
enhanced in neurons by various stresses, including electrical
stimulation, hypoxia-ischemia, oxygen-glucose deprivation
(Zhou et al., 2012), exercise-induced neuroplasticity (Ding
et al., 2006), injection of the neurotoxin 6-hydroxydopamine
(Park et al., 2010), and schizophrenia-induced oligodendrocyte
dysfunction (Bernstein et al., 2012). PHB1 is also upregulated
in the liver of steatohepatitis patients (Tsutsumi et al., 2009),
in fetal rabbit lung after exposure to hyperoxic conditions
(Henschke et al., 2006), in pancreatic b-cells after ethanol intox-
ication, (Lee et al., 2010b), and in cardiac cells after ischemic-
hypoxic preconditioning (Kim et al., 2006; Muraguchi et al.,
2010) or chronic restraint stress (Liu et al., 2004). This cytopro-
tectant response involves the translocation of PHB1 from the
nucleus and the cytoplasm to mitochondria in pancreatic b-cells
(Lee et al., 2010b), in the retina and retinal epithelium (Lee et al.,
2010a), and in ovarian granulosa cells (Chowdhury et al., 2007;
Figure S2). Sripathi et al. (2011) suggested that the localization
and trafficking of PHBs are determined by themodulation of their
binding to specific lipids. Indeed, strong binding of PHB1 to
cardiolipin was shown to correlate with the localization of
PHB1 within mitochondria in transformed epithelial cells after
an oxidative stress. By contrast, under normal conditions in
these cells, PHB1 binds strongly to PIP3 but not to cardiolipin.
Overexpression of PHB1 protects pancreatic b-cells, ovarian
granulosa cells, and cardiomyocytes from apoptosis induced
by ethanol, ceramide, staurosporine, serum withdrawal, and
oxidative stress-induced injury, consistent with PHB1 havingChemistry & Bioa cytoprotective role (Chowdhury et al., 2007, 2011; Lee et al.,
2010b; Liu et al., 2009b).
Merkwirth et al. (2012) recently describedacritical role of PHB2
in the survival of neurons.Neuron-specific deletion of PHB2 in the
mouse forebrain impaired mitochondrial architecture, leading to
tau hyperphosphorylation and filament formation. This pheno-
type was accompanied by severe behavioral and cognitive
dysfunctions that were reminiscent of Alzheimer’s disease.
The details of the mechanisms of this cytoprotection remain
poorly documented. The only other actors that have been iden-
tified as being involved are S1P and STAT3. S1P protects the
heart from ischemia-reperfusion damage by directly activating
PHB2, thereby regulating respiration and cytochrome oxidase
subunit IV assembly and decreasing the heart’s susceptibility
to opening of the permeability transition pore (PTP; Gomez
et al., 2011).
Interleukin-6 (IL-6) increases PHB1 levels through phosphory-
lation of the transcription factor STAT3 to promote the survival of
intestinal cells and cardiomyocytes (Gratia et al., 2012; Theiss
et al., 2007b). In intestinal epithelial cells in vivo, PHB1 interacts
with STAT3 to modulate STAT3-mediated apoptosis (Kathiria
et al., 2012b). In cardiomyocytes, IL-6-induced upregulation of
PHB1 is central to the cardioprotective effects of IL-6 against
oxidative stress (Gratia et al., 2012). Importantly, phosphorylated
STAT3 protects cardiomyocytes against oxidative stress by
stimulating respiration and inhibiting the PTP within mitochon-
dria, and not through a transcriptional effect (Boengler et al.,
2010). It would be interesting to determine whether PHB1modu-
lates this mitochondrial action of STAT3.
PHBs and Inflammatory Diseases
Inflammatory bowel diseases (IBDs) are characterized by
strong oxidative stresses associated with downregulated anti-
oxidant enzymes in the intestinal mucosa (Lih-Brody et al.,
1996). Several studies in vitro and in vivo have indicated that
PHB1 alleviates intestinal inflammation and promotes the
survival of cells exposed to oxidative stress. In intestinal epithe-
lial cells, PHB1 binds to a Salmonella typhi antigen to inhibit the
inflammatory response to S. typhi infection (Sharma and Qadri,
2004). PHB1 expression is abnormally low during ulcerative
colitis and Crohn’s disease, the two most common forms of
IBD (Hsieh et al., 2006; Theiss et al., 2007a; Yeo et al., 2006),
due to an overstimulation of tumor necrosis factor a (TNF-a)
signaling in the inflamed colon (Theiss et al., 2009a). This down-
regulation of PHB1 increases ROS signaling and TNF-a-in-
duced autophagy, promoting inflammation in patients with
IBD (Kathiria et al., 2012a). Interestingly, transgenic mice over-
expressing PHB1 in intestinal epithelial cells exhibit reduced
proinflammatory nuclear factor kB (NF-kB) signaling in the
colonic mucosa after treatment with TNF-a, demonstrating
that PHB1 plays a critical role in inflammation. A detailed exam-
ination of this mechanism of action revealed that PHB1 inhibits
TNF-a-induced translocation of NF-kB by downregulating the
expression of importin a3, a protein involved in NF-kB nuclear
import (Theiss et al., 2009a). In an in vivo model of IBD,
PHB1 transgenic mice exhibited lower oxidative stress and
colitis than wild-type mice (Theiss et al., 2009b). This cytopro-
tective effect is due to the upregulation of nuclear factor
erythroid 2-related factor 2 (Nrf2), a transcriptional activator oflogy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 319
Table 1. Proteins that Interact with PHBs
Binding Partners PHB Biological Consequences References
Mitochondrial Proteins
m-AAA protease PHB1 regulation of membrane protein
degradation
Steglich et al., 1999
ATAD3 PHB1 mitochondrial protein synthesis He et al., 2012
nucleoids (mitochondrial DNA
associated to nucleoproteins)
PHB1/2 maintenance of the organization
and copy number of the mtDNA
Kasashima et al., 2008
dynamin-like GTPase OPA-1 PHB1 stabilization of the structure of
mitochondria during their fusion
and morphogenesis
Merkwirth et al., 2008
subunits of cytochrome c oxidase PHB1 function of the mitochondrial
respiratory chain
Tsutsumi et al., 2009
NADH-ubiquinone oxidoreductase
30 kDa subunit
PHB1 stabilization of mitochondrial complex I Park et al., 2010
ND4 and ND5 PHB1 assembly of mitochondrial complex I Bourges et al., 2004
SLP-2 PHB1/2 stabilization of PHBs Da et al., 2008
TFAM PHB1 regulation of copy number of
mitochondrial DNA
Kasashima et al., 2008
ANT2 PHB2 unknown Kasashima et al., 2006
VDAC2 PHB2 unknown Kasashima et al., 2006
Hax-1 PHB2 stabilization of antiapoptotic Hax-1 Kasashima et al., 2006
nitric oxide-associated protein 1
(mNOA1)
PHB1 regulation of mitochondrial protein
translation and respiration
Heidler et al., 2011
phosphorylated p66ShcA PHB1 putative protection against oxidative
stress
Madireddi, 2006
Transcription Factors
estrogen receptor PHB1/2 repression of estrogen-receptor
activity
Delage-Mourroux et al., 2000; He et al.,
2008; Montano et al., 1999
E2Fs PHB1 repression of E2F activities Gamble et al., 2007; Joshi et al., 2003,
2007; Schneider et al., 2010
p53 PHB1 enhancement of p53-mediated
transcriptional activity and chaperone
activity of PHB1 for p53
Chander et al., 2011; Fusaro et al., 2003;
Joshi et al., 2007
MyoD and MEF2 PHB2 repression of MyoD and MEF2
activities
Sun et al., 2004, 2011
chicken ovalbumin upstream binding
transcription factors I and II
PHB2 transcriptional repression Kurtev et al., 2004
phosphorylated STAT3 PHB1 modulation of p53- and STAT3-
mediated apoptosis
Kathiria et al., 2012b
Other Nuclear Proteins
HDAC1 and HDAC5 PHB1/2 transcriptional repression Kurtev et al., 2004
Rb and its family members p107
and p130
PHB1 repression of E2F-mediated transcription
and inhibition of cell proliferation
Wang et al., 1999a, 1999b, 2002
Brg-1 and Brm PHB1 repression of E2F-mediated transcription
and inhibition of cell proliferation
Wang et al., 2002
heterochromatin protein 1 (HP1)
family proteins
PHB1 repression of E2F-mediated
transcription and induction of
cellular senescence
Rastogi et al., 2006a
RING finger protein 2 (RNF2) PHB1/2 repression of the transcriptional
activity of E2F1 and CP2c
Choi et al., 2008; Lee et al., 2008
histone methyltransferase EZH2 PHB2 repression of estrogen-dependent
transcription
Hwang et al., 2008
PGC1a (PPARg coactivator 1) PHB2 inhibition of the transcriptional
activity of PPARg
Endo, 2011
(Continued on next page)
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Table 1. Continued
Binding Partners PHB Biological Consequences References
minichromosomes maintenance
complex of proteins MCM2, MCM5,
and MCM 7
PHB1 inhibition of DNA replication Rizwani et al., 2009
nuclear receptor corepressor 1
(NCoR)
PHB1 transcriptional repression of E2F family
members
Wang et al., 2002
Other Signaling Proteins
IgM receptor PBH1 phosphorylation of PHB1 Terashima et al., 1994
protease-activated receptor 1 PHB1/2 platelet aggregation Zhang et al., 2012
C-Raf PBH1 phosphorylation of C-Raf by Ras and
consequently activation of the
MEK-eIF4 pathway
Chiu et al., 2012; Chiu et al., 2013;
Rajalingam et al., 2005
Akt2 PHB2 cell-cycle exit and myogenic differentiation He´ron-Milhavet et al., 2008; Sun et al.,
2004
WD repeat domain 5 (WDR5, BIG3) PHB2 inhibition of the translocation of PHB2
to the nucleus
Kim et al., 2009
Skp2B PHB1/2 attenuation of the transcriptional activity
of p53, release of the repression of the
estrogen receptor
Chander et al., 2010, 2011; Umanskaya
et al., 2007
MLK2 (mixed lineage kinase 2) PHB1 unknown Rasmussen et al., 1998
Shp1 (phosphatase) phospho-Y114-
PHB1
modulation of insulin signaling Ande et al., 2009a
PKC-d PHB1 phosphorylation of PHB1 leading to
a decrease in the inner mitochondrial
membrane permeability and to
cell survival
Zhu et al., 2010
14-3-3 protein PHB1 inhibition of PHB1 phosphorylation
leading to an increase in the inner
mitochondrial membrane permeability
and to apoptosis
Zhu et al., 2010
a-dystrobrevin PHB1 NB4 cell granulocytic differentiation Borutinskaite et al., 2011
transient Receptor Potential
Melastatin 6 (TRPM6)
PHB2 inhibition of TRPM6-mediated
transepithelial Mg2+ transport
Cao et al., 2009
HSP70 PHB1 resistance to stress Liu et al., 2010
glucose-regulated protein 75
(GRP75)/mortalin
PHB1 cell proliferation, tumorigenesis and
stress response in metastatic cells
Martı´n et al., 2008
phospho- Ser291- Syk PHB1 B cell antigen-receptor signaling Paris et al., 2010
CRM-1 PHB1 export of PHB1 outside of the nucleus
selectively in cancer cells
Rastogi et al., 2006b
Pex14p PHB1 regulation of the peroxisomal importomer Oeljeklaus et al., 2012
annexin A2 PHB1/2 interaction blocked by calcium,
association with lipid rafts
Zhu et al., 2010
alpha-actinin PHB1/2 interaction blocked by calcium,
association with lipid rafts
Bacher et al., 2002
EHD2 Palmitoylated
PHB1
inhibition of pyruvate carboxylase leading
to a decrease in glucose and fatty
acid oxidation
Ande and Mishra, 2010; Vessal et al.,
2006
C3 PHB1 enhancement of innate immunity response Mishra et al., 2007
CK1ε PHB2 inhibition of circadian transcription Kategaya et al., 2012
Proteins of Pathogens
SV40Tag (viral oncoprotein) PHB1 interruption of the association between
PHB1 and Brg-1/Brm
Wang et al., 2002
HIV-1 glycoprotein PHB1/2 viral spread in nonpermissive cells Emerson et al., 2010
DENV-2 E protein PHB2 internalization of the dengue virus Kuadkitkan et al., 2010
(Continued on next page)
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Table 1. Continued
Binding Partners PHB Biological Consequences References
Chikungunya virus E2 protein PHB1 internalization of the chikungunya virus Wintachai et al., 2012
SARS-CoV nonstructural protein
nsp2
PHB1/2 supposed disruption of intracellular host
signaling during SARS-CoV infection
Cornillez-Ty et al., 2009
Vi polysaccharide of Salmonella
typhi
PHB1/2 inhibition of the inflammatory response
upon infection with Vi- S. typhi.
Sharma and Qadri, 2004
capsid protein VP1 of foot-and-
mouth disease virus
PHB1 dephosphorylation of PHB T258 Chiu et al., 2012
macrophage surface HSP70 Leishmania
donovani PHB1
induction of a strong humoral response
in leishmaniasis patients
Jain et al., 2010
See also Table S1.
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therapeutic target for treating IBD comes from the observations
that adenovirus-directed administration by enema and nano-
particle-based colonic delivery of PHB1 effectively enhanced
the levels of PHB1 at the surface of colonic epithelial cells
and alleviated colitis induced by dextran sodium sulfate (Theiss
et al., 2011).
Picard et al. (2013) recently demonstrated that PHB1 accumu-
lates in the nucleus of osteoarthritic chondrocytes, where it
represses the expression of the transcription factor PITX1, sug-
gesting an involvement of PHB1 in the etiology of osteoarthritis.
In addition to PHB1, PHB2 is also involved in inflammation.
Indeed, heterozygous PHB2+/were shown to bemore sensitive
to liver insults and inflammatory aggressions than wild-type
animals, confirming a cytoprotective and anti-inflammatory role
of PHB2 in liver (Sa´nchez-Quiles et al., 2012).
Lucas et al. (2013) recently discovered how PHB1 and PHB2
induce an immune response in B cells. The interaction of CD86
with PHBs was shown to induce the phosphorylation of IkBa,
phospholipase Cg2, and protein kinase Ca/b(II), leading to the
nuclear translocation of NF-kB (p65) into the nucleus and the
subsequent transcription of Oct-2 and IgG1.
PHBs and Metabolic Diseases
Ande and Mishra (2009) and Ande et al. (2009a) established that
PHB1 is a key regulator of insulin signaling and adipocyte differ-
entiation. Indeed, PHB1 is directly phosphorylated by the insulin
receptor to promote insulin signaling and block Akt signaling,
whereas phosphorylation of PHB1 by Akt has the opposite
effect.
Interestingly, PHB1 is not only phosphorylated but is also
conjugated toO-linked b-N-acetylglucosamine in myoblast cells
in response to insulin and high glucose. This glucose-induced
O-GlcNAc modification and phosphorylation of PHB1 may be
associated with insulin resistance modification and tyrosine
phosphorylation of PHB (Ande et al., 2009b; Gu et al., 2011).
PHB1 inhibits pyruvate carboxylase and decreases insulin-
stimulated oxidation of glucose and fatty acid in adipocytes,
implying that it has a role in promoting lipid accumulation (Vessal
et al., 2006). Crosslinking experiments showed that PHB1 asso-
ciates with pyruvate carboxylase and Eps 15 homology domain
protein 2 (EHD2), suggesting that PHB1 shuttles between the
extracellular space and the mitochondria by a mechanism
involving lipid rafts and EHD2.322 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rRecently, Ande et al. (2012) demonstrated that treatment of
preadipocytes with insulin or a peroxisome proliferator-activated
receptor g (PPARg) agonist upregulates PHB1, thereby pro-
moting preadipocyte differentiation into adipocytes. Remark-
ably, overexpression of PHB1 was sufficient to induce adipo-
genesis. PHB1 on the cell surface is also a marker of adipose
vasculature and may be a possible therapeutic target for obesity
(see below).
PHBs and Pathogenic Agents
Several recent studies demonstrated that the internalization of
some viruses involves PHBs. For instance, PHB1 interacts
with chikungunya virus (Wintachai et al., 2012), PHB2 interacts
with dengue virus (Kuadkitkan et al., 2010), and both PHB1
and PHB2 interact with severe acute respiratory syndrome
coronavirus (SARS-CoV; Cornillez-Ty et al., 2009). PHB1 and
PHB2 also interact with the HIV-1 glycoprotein to promote repli-
cative spread in nonpermissive cells (Emerson et al., 2010).
Interestingly, recombinant capsid protein VP1 (rVP1) of foot-
and-mouth disease virus dephosphorylates Akt and phospho-
PHB Ttr258 in lipid rafts to downregulate C-Raf/ERK signaling
and inhibit metastasis of cancer cells, both in vitro and in vivo
(Chiu et al., 2012). Moreover, using high-throughput mass
spectrometry, Jang et al. (2012) discovered that lipoteichoic
acid, a major virulence factor of Gram-positive bacteria, binds
to PHB2, implicating PHB2 in host immune responses to
infections.
Drug Development Outlook
The activities of PHBs are affected by some natural products
(e.g., flavaglines and aurilide), fully synthetic small molecules
(e.g., melanogenin), and adipotide, a chimeric peptide that is
currently in phase I clinical trial. These compounds (except for
adipotide) were examined for a variety of activities before it
became clear that PHBs were their molecular targets. The
best-studied PHB ligands are flavaglines.
Flavaglines
Flavaglines have a unique cyclopenta[b]benzofuran skeleton
(Ebada et al., 2011; Ribeiro et al., 2012b). Rocaglamide, the first
of these compounds to be described, was isolated more than 30
years ago by King et al. (1982) frommedicinal plants of the genus
aglaia (Meliaceae) in Southeast Asia. Since then, 100 other fla-
vaglines, including rocaglaol and silvestrol, have been identified
(Figure 3A; Figure S3).ights reserved
Table 2. Roles of PHB Signaling in Cancer
Antitumorigenic Roles of PHBs References
PHB1 activates the tumor
suppressor p53
Chander et al., 2011; Fusaro
et al., 2003; Joshi et al., 2007
PHB1 interacts with the tumors
suppressors Rb, p107, and p130
to repress E2F-mediated transcription
and inhibit cell proliferation
Wang et al., 1999a, 1999b,
2002
PHB1 represses DNA replication by
interacting with components of the
mammalian replication machinery
Rizwani et al., 2009
Protumorigenic Roles of PHBs
PHB1 and PHB2 are necessary for
the activation of C-RAF by Ras
Rajalingam et al., 2005
phosphorylated PHB1 promotes the
survival of prostate cancer cells
Zhu et al., 2010
the oncomir miR-27a downregulates
PHB1
Liu et al., 2010; Fletcher
et al., 2012
localized on the cell surface, PHB1
mediates resistance to taxoids
Patel et al., 2010
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effects due to their anticancer, anti-inflammatory, neuroprotec-
tive, and cardioprotective properties, it is the anticancer proper-
ties that have attracted themost attention from scientists (Ebada
et al., 2011; Ribeiro et al., 2012b). At concentrations in the
low-nanomolar range, flavaglines inhibit the proliferation of
tumor cells, are not toxic to normal cells (Hausott et al., 2004;
Ribeiro et al., 2012a; Su et al., 2006; Thuaud et al., 2009, 2011;
Zhu et al., 2007), and show no sign of toxicity in mice (Bernard
et al., 2011; Cencic et al., 2009; Lee et al., 1998; Thuaud et al.,
2009; Zhu et al., 2009). King et al. (1982) were the first to demon-
strate the antileukemic activity of rocaglamide in amousemodel.
Subsequently, Ohse et al. (1996) established that flavaglines
strongly inhibit protein synthesis, and Lee et al. (1998) demon-
strated that these compounds delay the growth of human breast
cancer cells in athymicmice. However, because the tumorswere
not eradicated, these investigations were interrupted. Since
then, with the development of targeted therapies, approaches
to the development of cytostatic compounds have changed
radically (Gutierrez et al., 2009). As a consequence, there is
now a renewed interest in flavaglines as potential anticancer
agents.
Although flavaglines have shown significant anticancer effects
in mouse models of cancer (Alinari et al., 2012; Cencic et al.,
2009; Hwang et al., 2004; King et al., 1982; Lee et al., 1998;
Lucas et al., 2009; Meurer-Grimes et al., 2002; Thuaud et al.,
2011), their most promising potential is associated with their
ability to enhance the in vivo efficacy of other anticancer drugs,
and in particular to relieve the resistance of tumors to chemo-
therapies. Indeed, flavaglines were shown to enhance doxoru-
bicin chemosensitivity in several mouse lymphoma models
(Bordeleau et al., 2008; Cencic et al., 2009; Zhu et al., 2009).
Importantly, flavaglines did not display any overt sign of toxicity
in mice in these studies, consistent with previous observations.
Very recently, using affinity chromatography-coupled mass
spectrometry, Polier et al. (2012) identified PHB1 and PHB2 asChemistry & Biothe direct targets of flavaglines. The binding of flavaglines
to PHBs inhibits Ras-C-Raf-MEK-ERK signaling, and such
signaling is essential for the survival of cancer cells (Figure 3B).
C-Raf needs to interact with PHBs to be phosphorylated by
Ras and thus participate in signaling (Rajalingam et al., 2005).
The binding of flavaglines to PHBs prevents this interaction
both in vitro and in vivo. Knockdown of either PHB1 or PHB2
with small interfering RNA (siRNA) mimicked the effects of fla-
vaglines through inhibition of cap-dependent translation and
an arrest of cell-cycle progression via a depletion of cyclin D3,
CDK4, CDK6, and cdc25A. Moreover, rocaglamide strongly
depleted PHB1 and phosphorylated C-Raf at the plasma mem-
brane, suggesting that the relocation of PHBs to the membrane
is involved in the mode of action of flavaglines. These various
observations support the idea that flavaglines exert their anti-
cancer effects through their action on PHBs.
These findings are of particular interest because we now have
evidence that Ras-C-Raf-ERK constitutes an overactivated
pathway in many human cancers, and that this pathway is
a promising target for treatments in oncology (Matallanas
et al., 2011; Maurer et al., 2011). Bleumink et al. (2011) showed
that this inhibition of C-Raf-ERK signaling blocks cap-dependent
protein synthesis. Indeed, ERK activates Mnk1, which phos-
phorylates eIF4E, allowing cap-dependent synthesis to occur.
Few proteins require phosphorylated eIF4E for their synthesis,
and most of them are involved in oncogenesis, angiogenesis,
and chemoresistance. Thus, the in vivo anticancer effects of
flavaglines seems to be a consequence of the inhibition of the
synthesis of cyclins D1 and D3, CDK4, CDK6, cdc25A c-Myc,
Bcl-2, survivin, Mcl-1, the PIM1/2 kinases, vascular endothelial
growth factor (VEGF), and matrix metallopeptidase 9 (MMP9)
(Bordeleau et al., 2008; Cencic et al., 2009; Nasr et al., 2013;
Polier et al., 2012; Schatz et al., 2011).
Although inhibition of the Ras-C-Raf-ERK signaling pathway
may be involved in the flavagline-induced suppression of cap-
dependent synthesis in cells (Bleumink et al., 2011), it is more
difficult to explain the observed inhibition of protein synthesis
in vitro, where C-Raf, MEK, and ERK are absent. This observa-
tion suggests either that another molecular target is involved in
the inhibition of translation by flavaglines or that PHBs interact
with the translational machinery to control its activity.
Flavaglines induce apoptosis in cancer cells through a myriad
of mechanisms (Ribeiro et al., 2012b) involving cytochrome c
(Mi et al., 2006b; Zhu et al., 2007), apoptosis-inducing factor
(Thuaud et al., 2009), caspase 12 (Thuaud et al., 2009), and the
MAPKs JNK and p38 (Zhu et al., 2007, 2009). Whether these
mechanisms involve PHB1 and PHB2 or another target remains
to be determined. The effect of flavaglines on PHBs-interacting
proteins other than C-Raf is also an issue that needs to be
examined.
Silvestrol is the flavagline that has been the most studied
in vivo for its anticancer properties (Alinari et al., 2012; Bordeleau
et al., 2008; Cencic et al., 2009; Hwang et al., 2004; Kim et al.,
2007; Mi et al., 2006a; Robert et al., 2009; Schatz et al., 2011).
However, the development of this compound is severely limited
by its sensitivity to P-glycoprotein-mediated multidrug resis-
tance and its suboptimal absorption, distribution, metabolism,
and excretion (ADME) characteristics (Gupta et al., 2011; Liu
et al., 2012). Fortunately, structure-activity relationship (SAR)logy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 323
Figure 3. Structure and Pharmacological
Actions of Flavaglines
(A) Structure of selected natural (rocaglamide,
rocaglaol, and silvestrol) and synthetic (FL3, FL40,
and IMD-019064) flavaglines.
(B–E) Proposed models of the mode of action of
flavaglines in cancer cells (B), lymphocytes (C),
glial cells (D), and cardiomyocytes (E).
See also Figure S2, which illustrates the trans-
localization of PHB1 to mitochondria in noncan-
cerous cells to promote survival.
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the amide in position 2 results in compounds that escape this
multidrug resistance without any loss of cytotoxicity (Figure S3;
Ribeiro et al., 2012a; Thuaud et al., 2009, 2011).
In addition to their anticancer effects, flavaglines also display
potent anti-inflammatory and neuroprotective activities. Indeed,
flavaglines at nanomolar concentrations act as immunosuppres-
sors by inhibiting the production of interferon-g, TNF-a, IL-2, and
IL-4 by T lymphocytes (Proksch et al., 2005). This immunosup-
pression is mediated by activation of the MAPKs JNK and p38,
which selectively inactivate nuclear factor of activated T cells
(NFAT; Figure 3C). It is still not known how flavaglines activate
JNK and p38. At higher concentrations, flavaglines also inhibit
NF-kB, another transcription factor that is involved in inflamma-
tion (Baumann et al., 2002). Interestingly, the synthetic flavagline
IMD-019064 inhibits NF-kB signaling and displays potent
in vitro anti-inflammatory effects that manifest as an inhibition324 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rights reservedof proinflammatory mediator release
from astrocytes, microglia, and endothe-
lial cells (Fahrig et al., 2005; Figure 3D).
More importantly, IMD-019064 protects
dopaminergic neurons both in vitro and
in vivo in models of Parkinson’s disease
(MPP+-induced neurotoxicity) and trau-
matic brain injury. Recent SAR studies
led to the identification of FL40, which
provides greater neuroprotection in vitro
than IMD-019064 (Ribeiro et al., 2012a).
The neuroprotective activity of flavaglines
is currently being actively explored by
the pharmaceutical company Intermed
Discovery, which has been developing
IMD-026259 (Figure 3A) for the treatment
of Parkinson’s disease.
These studies have prompted evalua-
tions of the cytoprotective potential of fla-
vaglines in other tissues. The synthetic
flavagline FL3 (Figure 3A), which displays
a potent cytotoxicity in cancer cells
(Thuaud et al., 2009), was shown to
protect cardiomyocytes in vitro and
in vivo against various stresses, includ-
ing anthracycline cardiotoxicity (Bernard
et al., 2011). The heart is extremely sensi-
tive to the toxicity of anthracyclines, such
as doxorubicin. These medicines are
among the most effective anticancerdrugs available and have antitumor activity against both hemato-
poietic and solid tumors; unfortunately, their clinical utility is
markedly hampered by their cardiotoxicity, which can lead to
dilated cardiomyopathy and congestive heart failure (Minotti
et al., 2004).
FL3 protects cardiomyocytes from the apoptosis induced by
both doxorubicin and serum starvation (Bernard et al., 2011).
Interestingly, these stresses are of different natures: doxorubicin
causes an oxidative stress, whereas serum starvation blocks
the growth factor signaling that is necessary for cell survival,
mimicking an important component of myocardial ischemia.
Treatment with FL3 significantly reduces mortality and attenu-
ates both apoptosis and fibrosis in the hearts of doxorubicin-
treated mice. Thus, flavaglines may both enhance the anticancer
efficacy of anthracyclines and alleviate their main adverse effect,
cardiotoxicity. Anthracyclines are central to cancer chemother-
apies, so the discovery of a new class of cardioprotective agents
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examine this therapeutic application are therefore warranted.
The cardioprotective effects of flavaglines are mediated
through the phosphorylation of the small heat shock protein
Hsp27 (Figure 3E). Hsp27 is critical for protecting cells against
many types of damage, including the cardiotoxicity of doxoru-
bicin, and exerts its effects in several ways, including chaperone
activity, control of redox homeostasis, and inhibition of apo-
ptosis (Kostenko and Moens, 2009). Whether PHBs or another
target is involved in this cardioprotective effect of flavaglines
has not been examined.
Although the cytoprotective and anti-inflammatory effects of
flavaglines have not yet been demonstrated to be mediated
through a binding to PHBs, it is unlikely that another target is
involved. Indeed, both their pharmacological effects and cyto-
toxicity in cancer cells occur at the same range of concentra-
tions. As far aswe know, no other natural product that possesses
such a complex three-dimensional structure has been shown to
bind to different classes of proteins with a comparably high
affinity.
It would be useful to further evaluate this therapeutic applica-
tion of flavaglines and elucidate the mechanisms involved. It
may seem odd than an anticancer drug can also display various
cardio- or neuroprotective effects; however, there are prece-
dents. For example, rapamycin derivatives (Erlich et al., 2007;
Khan et al., 2006; Malagelada et al., 2010) and HDAC inhibitors
are both cardio- and neuroprotectants in addition to having anti-
cancer effects (Bush and McKinsey, 2009; Mai et al., 2009). A
first clue to understanding this paradox may be that PHB1 is
localized mainly in the mitochondria of normal cells and in the
nucleus in cancer cells (Chen et al., 2011). The translocation
of PHB1 from the nucleus and cytosol to mitochondria
promotes survival in normal cells but apoptosis in cancer cells
(Fusaro et al., 2003). It is therefore tempting to suggest that
the opposite behaviors of flavaglines in cancer and normal
cells are the consequences of different intracellular localizations
of PHBs.
Although many academic studies have demonstrated a thera-
peutic potential of flavaglines in preclinical models of cancers
and inflammatory and cardiac diseases, these compounds
have not yet been examined in a clinical trial. To our knowledge,
only two pharmaceutical companies (Intermed Discovery and
Infinity Pharmaceutical) are currently developing flavaglines
for the treatment of Parkinson’s disease and cancers, respec-
tively.
Aurilide
Isolated from the Japanese sea hare (Dolabella auricularia;
Suenaga et al., 2004; Suenaga et al., 1996), aurilide is a cyclic
depsipeptide that displays a strong cytotoxicity at nanomolar
and subnanomolar concentrations on a panel of cancer cell lines
(Figure 4A; Figure S4). Work involving affinity chromatography
identified PHB1 as the molecular target of aurilide (Sato et al.,
2011). The binding of this toxin activates the proteolytic process-
ing of the dynamin-like GTPase optic atrophy 1 (OPA1), which in
turn triggers remodeling of the mitochondrial cristae, leading to
apoptosis. This devastating effect on mitochondria probably
explains the extreme toxicity of this compound, which impedes
its study in animal models and precludes its further development
as a medicament.Chemistry & BioMelanogenin
In a quest to identify compounds that modulate skin pigmenta-
tion, Snyder et al. (2005) screened a tagged-triazine library on
unpigmentedmelanocytes (Figure 4B; Figure S5). They identified
melanogenin as an inducer of pigmentation with an EC50 of
2.5 mM. This compound upregulates tyrosinase, the rate-limiting
enzyme in the biosynthesis of melanin.
Snyder et al. (2005) conjugated melanogenin to an agarose
support, which enabled them to identify PHB1 as the molecular
target by affinity chromatography. Further biological investiga-
tions confirmed that PHB1 is responsible for the induction of
pigmentation. Immunofluorescencemicroscopy studies showed
that PHB1 was localized only in mitochondria, which led these
authors to suggest that the binding of melanogenin to PHB1
may disrupt the interaction between PHB1 and a transcriptional
factor, thereby causing its translocation to the nucleus and
induction of the expression of tyrosinase, the rate-limiting
enzyme in melanogenesis.
This study was the first to demonstrate and unravel the
involvement of PHB1 in the regulation of mammalian pigmenta-
tion. Although these discoveries may provide a basis for the
development of novel cosmetics and drugs for the treatment of
pigment disorders, no further investigation in this direction has
been reported.
Recently, Wu and Wu (2012) demonstrated that PHB1 is
enriched in lipid rafts in HaCaT keratinocytes after UVB irradia-
tion, and that this protects the cells against UVB-induced
apoptosis. These findings are consistent with the notion that
PHB1 contributes to protection of the skin against UVB.
Adipotide
Kolonin et al. (2004) and Staquicini et al. (2011) used phage
display techniques to identify a peptide homologous to a
region of annexin A2 that targets PHB1 at the surface of the
vascular endothelial cells of white adipose tissue (Figure 4C).
By fusion with a proapoptotic sequence, they obtained adipo-
tide (CKGGRAKDC-GG-D(KLAKLAK)2), a chimeric peptide that
damages the vasculature of the adipose tissue and conse-
quently disrupts the blood supply to adipocytes. In obese
mice, adipotide induced a substantial loss of weight and normal-
ized metabolism, leading to a reversal of obesity without any
adverse sign of toxicity. Surprisingly, food intake was reduced,
suggesting that there is an unexpected relationship between
the adipose tissue vasculature and the regulation of feeding
behavior (Kim et al., 2010).
In obese rhesus monkeys, 4 weeks of adipotide treatment led
to a 28% reduction in body fat and also reduced food intake and
improved the animals’ metabolic status (i.e., reduced insulin
resistance); these findings have implications for the develop-
ment of treatment for type 2 diabetes (Barnhart et al., 2011). Adi-
potide is currently being developed by the biotech company
Arrowhead Research Corporation, and entered a phase I trial
involving obese patients with prostate cancer in July 2012.
Because adipotide has a negative endocrine effect on tumor
growth, it is expected to slow tumor growth in these patients.
Capsaicin
Capsaicin is a component of hot chili peppers that inhibits the
proliferation of many cancer cell lines. Using affinity chroma-
tography, Fletcher et al. (2012) demonstrated that capsaicin
(0.1–1 mM) binds to PHB2, and that this binding induceslogy 20, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 325
Figure 4. Proposed Mechanism of Action of
Various PHB Ligands
(A) Aurilide is a cytotoxic depsipeptide that binds
to PHB1 and triggers remodeling of the mito-
chondrial cristae to lead to apoptosis.
(B) Melanogenin binds to PHB1 to induce the
expression of tyrosinase, the rate-limiting enzyme
in melanogenesis.
(C) Adipotide is a chimeric peptide that targets
PHB1 at the surface of the vascular endothelial
cells of white adipose tissue. Its proapoptotic
sequence is responsible for the damage to this
tissue.
(D) Binding of capsaicin to PHB2 induces its
translocation from mitochondria to the nucleus,
a noncompetitive inhibition of the ANT2 and
the release of cytochrome c into the cytosol,
leading to the apoptosis of myeloid leukemia
cells.
(E) Sulfonyl amidine (A) inhibits the osteoclasto-
genesis involved in bone remodeling. This com-
pound binds to PHB1 and three other proteins.
Which of these proteins is the relevant target
involved in this antiresorptive activity remains
unknown.
(F) Aftin-4, which binds to PHB1, VDAC1, and
mitofilin, promotes in neurons the production of
the neurotoxic peptide Ab42, which is involved in
the etiology of Alzheimer’s disease.
(G) The dihydrooxazole cHOxa alkylates PHB1,
suggesting that it could be used as a chemical
probe to analyze the structure of PHB1.
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cells, including (1) the translocation of PHB2 from mitochondria
to the nucleus; (2) the dissociation of PHB2 from Adenine
Nucleotide Translocator 2 (ANT2), leading to a noncompeti-
tive inhibition of ANT activity; and (3) the release of cyto-
chrome c into the cytosol (Figure 4D). The latter two effects
could be caused by the depletion of PHB2 in mitochondria,
which would compromise mitochondrial integrity and promote
apoptosis.
Capsaicin was used in these experiments at concentrations
that are much too high to be therapeutically relevant, but this
work may constitute the basis for an optimization program to
develop a clinically useful drug.
Sulfonyl Amidine Derivatives
Sulfonyl amidine A inhibits the osteoclastogenesis involved in
bone remodeling with an IC50 of 1.8 mM (Lee et al., 2010c;
Figure 4E). Chang et al. (2011) used affinity chromatography to
identify the molecular target involved in this process and found326 Chemistry & Biology 20, March 21, 2013 ª2013 Elsevier Ltd All rights reservedthat this compound binds to PHB1 and
three other proteins. Which of these
proteins is the relevant target involved in
this antiresorptive activity remains to be
determined.
Aftin-4
While investigating how the toxic
amyloid-b42 (Ab42) peptide is produced
in Alzheimer’s disease, Bettayeb et al.
(2012) observed that the adenine deriva-
tive Aftin-4 promotes Ab42 production in
neurons (Figure 4F). Aftin-4 was found
to interact with three proteins relatedto neural degeneration: PHB1, voltage-dependent anion channel
1 (VDAC1), and mitofilin.
cHOxa
The dihydrooxazole cHOxa, which displays some cytotoxicity
with a GI50 of 7.2 mM in B16F0 cells, was shown to alkylate the
Asp40 of PHB1, suggesting that it could be used as a chemical
probe to analyze the structure of PHB1 (Trzeciakiewicz et al.,
2011; Figure 4G).
Conclusions
The regulation by PHBs of cell survival, apoptosis, metabolism,
and inflammation makes these proteins promising therapeutic
targets for novel treatments for cancer and neurodegenerative,
metabolic, and inflammatory diseases. Their intracellular locali-
zation and their translocation in response to proapoptotic signals
differ substantially between normal and cancer cells. This diver-
gence of behavior, which is not fully understood, may be
exploited to develop therapeutic agents. The phase I trial of
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Reviewadipotide for the treatment of obese patients with prostate
cancer may be the first step on the road to developing PHB
ligands of clinical value. The recent discovery that flavaglines
target PHBs warrants further studies of this class of anticancer
and cytoprotective agent. In addition to the ongoing exploration
of the roles of PHBs in physiology and physiopathology, we
anticipate that this field will stimulate research addressing other
classes of PHB ligands with original pharmacological properties.
Over the last few years, PHBs have been found to interact with
more than 60 other proteins to regulate a myriad of cellular
events. There is no doubt that in the coming years, new partners
and new cellular regulations will be uncovered. An important
issue will be to determine when the alterations of PHB expres-
sion, subcellular localization, and signaling are involved in the
etiology of not only cancers but also cardiac, neurological,
inflammatory, and metabolic diseases. Translating this knowl-
edge into clinical applications may lead to the development of
new medicines and biomarkers for diagnosis and prognosis.
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